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Abstract
The presence of oligoclonal bands (OCB) in cerebrospinal fluid (CSF) is a typical finding in multiple sclerosis (MS). We applied
data from Norwegian, Swedish and Danish (i.e. Scandinavian) MS patients from a genome-wide association study (GWAS) to
search for genetic differences in MS relating to OCB status. GWAS data was compared in 1367 OCB positive and 161 OCB
negative Scandinavian MS patients, and nine of the most associated SNPs were genotyped for replication in 3403
Scandinavian MS patients. HLA-DRB1 genotypes were analyzed in a subset of the OCB positive (n = 2781) and OCB negative
(n = 292) MS patients and compared to 890 healthy controls. Results from the genome-wide analyses showed that single
nucleotide polymorphisms (SNPs) from the HLA complex and six other loci were associated to OCB status. In SNPs selected
for replication, combined analyses showed genome-wide significant association for two SNPs in the HLA complex;
rs3129871 (p = 5.7610215) and rs3817963 (p = 5.7610210) correlating with the HLA-DRB1*15 and the HLA-DRB1*04 alleles,
respectively. We also found suggestive association to one SNP in the Calsyntenin-2 gene (p = 8.8361027). In HLA-DRB1
analyses HLA-DRB1*15:01 was a stronger risk factor for OCB positive than OCB negative MS, whereas HLA-DRB1*04:04 was
associated with increased risk of OCB negative MS and reduced risk of OCB positive MS. Protective effects of HLA-
DRB1*01:01 and HLA-DRB1*07:01 were detected in both groups. The groups were different with regard to age at onset
(AAO), MS outcome measures and gender. This study confirms both shared and distinct genetic risk for MS subtypes in the
Scandinavian population defined by OCB status and indicates different clinical characteristics between the groups. This
suggests differences in disease mechanisms between OCB negative and OCB positive MS with implications for patient
management, which need to be further studied.
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Introduction
Multiple sclerosis (MS) is an inflammatory disorder of the
central nervous system leading to demyelination and axonal
damage. The cause of MS is unknown, but studies support a
multifactorial etiology [1]. The association of MS to genes in the
major histocompatibility complex (MHC) was early established
[2], and carriers of the HLA-DRB1*15:01 allele have more than
three times increased risk for the disease [3]. In recent years,
genome-wide association studies (GWAS) have identified more
than 50 additional non-HLA loci associated with MS susceptibility
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[3,4]. However, none of the published MS GWAS have analyzed
phenotypes defined by CSF findings.
The presence of OCB in CSF and not in the corresponding
serum is an important diagnostic tool in MS and is thought to
reflect a local B-cell response of unknown specificity and
significance [5–8]. Up to 95% of MS patients in Northern Europe
have OCB in the CSF, but this frequency varies depending on
laboratory routines, study populations and was recently also
related to latitude [8–10]. The absence of OCB in CSF has been
claimed to be associated with a better, worse or equal clinical
outcome compared to OCB positive MS [10–18]. Various findings
are also reported for the genetic risk to OCB status conferred by
HLA-DRB1 alleles. Several studies have shown that the HLA-
DRB1*15 allele is associated with OCB positive MS [12,18,19]
(Leone et al. personal communication), or confer a stronger risk
for OCB positive MS than OCB negative MS [14,17]. OCB
negative MS has shown association to the HLA-DRB1*04:04/
04:05 alleles [12,19], or the HLA-DRB1*03:01 allele and the
HLA-DRB1*03:01/*04:01 and HLA-DRB1*13:01/15:01 geno-
types [17].
On this background, we aimed to further investigate genetic
differences between OCB positive and negative MS patients by
using the genotype data obtained from the Scandinavian sample
set (Norwegian, Swedish and Danish) included in a recent MS
GWAS [3]. In a screening phase, we looked for association
between genome-wide SNP data and OCB status in Scandinavian
MS patients. Replication was subsequently attempted by geno-
typing an independent Scandinavian sample set including more
than twice as many patients as the initial screening. Finally, we
analyzed HLA-DRB1 genotype data in relation to OCB status and
compared with healthy controls. Data on gender, AAO, clinical
course and the MS outcome measures Expanded Disability Status
Scale (EDSS) and Multiple Sclerosis Severity Score (MSSS) were
also available for analyses. To our knowledge, this study includes
the largest sample set to date used to investigate genetic
susceptibility to OCB status and detects differences in genetic risk
to OCB negative and positive MS conferred mainly by HLA-
DRB1 alleles.
Materials and Methods
Ethics Statement
The study was approved by the regional ethical committees in
each country involved; The regional Committee for Medical and
Health Research Ethics (REC)- South East and REC-West
(Norway), the Danish Ethical Committee Review Board for
Copenhagen and Frederiksberg (Denmark) and the Regional
Ethical Review Board in Stockholm (Sweden). The informed
written consent was obtained for all Norwegian and Danish
samples included. The Swedish samples were collected in five
different studies. For four of them informed written approval was
obtained from the patients and controls, but for one of them only
informed oral approval was obtained. The reason for this was that
written approval was not mandatory at the time of collection of
these samples. The procedure was such that no samples were taken
unless oral approval was obtained, but no additional documen-
tation was kept regarding the approval to participate in the study.
This procedure was approved by the Regional Ethical Review
Board in Stockholm.
Patients and Controls
The screening phase initially included 1574 MS patients
collected in Norway (n = 899), Denmark (n= 244) and Sweden
(n = 431). In the replication phase, 3568 additional samples from
Norway (n= 1236), Sweden (n= 1390) and Denmark (n= 942)
underwent genotyping. All MS patients were diagnosed in
accordance with the Poser and/or McDonald criteria [5,6]. The
analyses further included 428 Swedish healthy controls from the
EIMS study [20] and 890 healthy controls from the Norwegian
bone marrow donor registry.
CSF Analyses
CSF analyses were performed by isoelectric focusing with
immunoblotting (IEF), agarose gel electrophoresis (AGE) and/or
measures of IgG index (CSF/serum IgG:CSF/serum albumin). A
patient was characterized as OCB positive if oligoclonal bands
were detected in the CSF by IEF or AGE and/or in the presence
of increased IgG index. A patient was described as OCB negative
only in the absence of OCB detection on IEF or AGE. Less than
3% of the patients had measures of IgG index only.
Genome-wide SNP Data and SNPs for Replication
In the screening phase genotype data from 580,030 SNPs from
the International Multiple Sclerosis Genetics Consortium
(IMSGC) and Wellcome Trust Case Control Consortium2
(WTCCC2) GWAS was available for association analyses to
OCB status in 1406 OCB positive and 168 OCB negative MS
patients and 428 Swedish controls [3]. After quality control,
495,970 SNPs were left for analyses in 1528 patients (1367 OCB
positive and 161 negative). All samples were genotyped by the
Illumina Human 660-Quad chip performed on the Illumina
Infinium platform at the Wellcome Trust Sanger Institute as
described previously [3].
Nine of the top hit SNPs identified in the screening phase were
selected for replication in accordance with the following criteria; p-
value from the screening phase ,1025, level of deviation from
HWE p.0.001, minor allele frequency (MAF) .5% (all SNPs but
rs11790235 on chromosome 9) and the suitability of the context
sequences for design of primers. GWAS cluster plots for all
replicated SNPs were inspected specifically for the Scandinavian
samples. Two SNPs located in the PRKRA gene were excluded as
their context sequences also aligned to the MS associated gene
HLA-DRB1. All the SNPs in the HNMT gene on chromosome 2
(n= 14) were in high or complete linkage disequilibrium (LD) (r2
and D’: 0.98-1). We selected three of these SNPs for genotyping
from different regions (intron 1 and 39UTR). The context
sequences were obtained from UCSC Genome Browser dbSNP
132, Human Feb. 2009 assembly (http://genome.ucsc.edu/) [21].
Genotyping
The SNPs selected for replication were genotyped by Sequenom
technology (San Diego, Ca, USA). Duplicates from the screening
(n= 174) and within the replication (n= 120) were genotyped as
positive controls. HLA-DRB1 genotypes of two digit resolution for
405 Norwegian patient samples were available from previous
studies [22,23], and four digit HLA typing in the remaining
Norwegian patients (n = 1652) and healthy Norwegian controls
(n = 890) was performed by a sequence based approach [24]. HLA
typing in the Swedish samples was performed as previously
described [25]. Of the Swedish samples included in our HLA-
DRB1* genotype analyses, only 18 samples overlapped with the
previous study by Imrell et al. [12].
Statistical Analyses
Association testing of OCB status to the clinical parameters
gender, AAO, clinical course, MS outcome measures (EDSS and
MSSS) was performed by chi square testing (disease course and
Genetic Risk of Oligoclonal Band Status in MS
PLOS ONE | www.plosone.org 2 March 2013 | Volume 8 | Issue 3 | e58352
gender), two sample t-tests assuming equal variances (AAO) and
Wilcoxon signed rank test (EDSS and MSSS). PLINK software
v.1.06 (http://pngu.mgh.harvard.edu/purcell/plink/) [26] was
used in quality control. In the screening, individuals with .1%
missing genotypes, excess homo-/heterozygosity or who were
related (pi hat ,0.2) and SNPs with call rates ,98% or having
failed internal quality control at Sanger were excluded [3]. In the
replication, individuals with .4/9 missing genotypes were
excluded (n = 165). Population heterogeneity was assessed by
principal component plots and genomic inflation factor l
(screening) and Breslow Day testing (replication). SNP association
testing to OCB status was performed by logistic regression analyses
applying an additive genotype model including AAO as a
covariate. Combined analyses were performed by fixed effects
meta-analyses. R 2.12.1 (www.r-project.org) was used in SNP
association analyses, conditional logistic regression testing and
correlation coefficient estimations. HLA-DRB1 allelic association
testing was performed in Unphased 03.01.10 where allelic
frequency threshold was set to 5% [27]. The odds ratio (OR)
and confidence interval (CI) for each associated HLA-DRB1 allele
were calculated by specifically testing the risk of the associated
allele against all other HLA-DRB1 alleles with frequencies above
5% pooled together.
Results
Genetic Association to OCB Status
Initial analyses of clinical parameters in relation to OCB status
revealed nominal association of OCB status to AAO (p= 0.05)
(Table 1). Hence AAO was included as a covariate in all
subsequent analyses. In the genome-wide screening phase
495,970 SNPs were left for analyses in 1528 patients (1367 OCB
positive and 161 negative) after quality control. In subsequent
logistic regression analyses, 31 SNPs located in seven different
genetic regions, including the MHC, showed a trend for
association to OCB status (p,1025) (Table S1). We found no
evidence of population heterogeneity (l=1) and inclusion of the
first four principal components gave comparable results (Table
S1).
When genotype frequencies in OCB negative and OCB positive
patients were compared to Swedish healthy controls (n = 428)
genotyped in the same GWAS [3] (Table S2), nearly all the
identified non-HLA SNPs showed association to the OCB
negative group only. On the other hand, all but two SNPs in
the MHC (rs34083746 and rs3957148) showed significant
association only to the OCB positive group. Rs34083746, located
within HLA-DRB1, showed association of opposite effects in the
OCB positive and OCB negative group, whereas rs3957148 near
HLA-DQA2 showed association to the OCB negative group only.
In the replication phase, nine of the 31 SNPs were analyzed in
3403 individuals (n = 3029 OCB positive and n= 374 OCB
negative) (Table 2). These SNPs were selected in accordance with
the criteria described in materials and methods. All SNPs had
genotyping call rates above 97% and were in Hardy Weinberg
equilibrium (HWE) (p.0.05) in both patient subgroups, except
rs3817963 (HWE p-value = 4.861024). In order to exclude that
the deviation from HWE was due to genotyping error, we
manually inspected the cluster plots of this SNP to ensure that the
clusters from each genotype was distinctly separated and that no
genotype appeared to have systematically dropped out. Further-
more, there were no missing genotypes in the screening phase and
only 1% missing genotypes in the replication phase (32 out of
3403) for rs3817963. Since this genetic region is known to be
highly disease associated, and the genotyping results appeared to
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be of good quality, a possible explanation for the deviation from
HWE is that the genotype data arrived from cases only.
Associations to OCB status were replicated for the two SNPs
included from the MHC region; rs3817963 (p-value = 8.661026,
OR 1.51) and rs3129871 (p-value = 2.8610210, OR 1.69). In
addition, rs17411949 in the CLSTN2 gene on chromosome 3
showed nominal significant association (p-value 0.02, OR 1.47).
No other SNP showed association in the replication phase
(p.0.05). Breslow-Day testing showed no significant population
heterogeneity, and adjusting for population stratification revealed
comparable results (data not shown).
Combining the results from the screening and replication
phases, revealed genome-wide significant associations to OCB
status for the two HLA-SNPs rs3817963 (pcombined = 5.7610
210,
OR 1.61) and rs3129871 (pcombined = 5.7610
215, OR 1.72) and
suggestive evidence that rs17411949 in the CLSTN2 gene
(pcombined = 8.8610
27, OR 1.85) increases risk of OCB negative
MS (Table 2). Combined analysis of the clinical parameters in
relation to OCB status (Table 1), showed that the OCB negative
patients had significantly lower MSSS (4.05 vs. 4.40, p = 0.02),
older AAO (34.2 vs. 33.0, p = 0.01) and were more likely to be
male (p = 0.02).
HLA-DRB1*15:01 and *04:04 are Associated with OCB
Status
In order to investigate for correlation of the associated SNPs in
the MHC region to common HLA-DRB1 alleles, we calculated
their correlation coefficients to HLA-DRB1 genotypes available in
822 of the 859 Norwegian samples included in the screening
phase. All the HLA SNPs showed strongest correlation with either
DRB1*15 or DRB1*04 alleles (r.=0.65) (Table 3 and Table S3).
We therefore analyzed the association of the HLA-SNPs in the
GWAS screened Norwegian samples again, conditioning on the
HLA-DRB1*15 and *04 alleles, whereby association of all HLA-
SNPs became non-significant (Table 3).
Since our analyses implied that associated HLA-SNPs from the
screening likely reflected signals from the HLA-DRB1 *04 and *15
alleles, we performed a third stage of analyses of HLA-DRB1
genotypes in relation to OCB status. HLA-DRB1 genotype data
with two digit resolution was available for a subset of the
Norwegian (n= 2068) and Swedish MS patients (n = 1005)
(including in total 292 OCB negative patients). When comparing
HLA-DRB1 allele frequencies in OCB negative and OCB positive
MS patients, HLA-DRB1*15 conferred relative protection for
OCB negative MS (p-value = 1.2861027, OR 0.59, 95% CI 0.48–
0.73) and HLA-DRB1*04 increased risk of OCB negative MS
compared with OCB positive MS (p-value = 1.4661027, OR 1.80,
95% CI=1.44–2.25) (data not shown).
To refine the HLA-DRB1 association, we used HLA-DRB1
genotypes of four-digit resolution available for 1652 of the
Norwegian MS samples and 890 healthy Norwegian controls
(Table 4). Comparing OCB negative (n = 199) and OCB positive
(n = 1453) MS patients showed that HLA-DRB1*15:01 and HLA-
DRB1*04:04 were significantly differently distributed between
OCB positive and OCB negative MS patients (p*15:01 = 9.9610
25,
OR=0.64, 95% CI 0.49–0.83, p*04:04 = 0.0004, OR=2.2, 95%
CI= 1.5–3.20). As expected, the HLA-DRB1*15:01 subtype
accounted for the majority of the HLA-DRB1*15 allele group
(99,8% in the OCB positive patients and 100% in the OCB
negative patients). On the other hand, the HLA-DRB1*04:04
subtype accounted for a larger proportion of DRB1*04 among the
OCB negative patients (43,7%) than the OCB positive (34,1%).
Shared Effects at the HLA-DRB1*15:01, *01:01, *07:01 Loci
and Opposite Effects at the HLA-DRB1*04:04 Allele
Compared to healthy controls the HLA-DRB1*15:01 was a risk
allele for both CSF subtypes, but conferred a stronger risk on OCB
positive than OCB negative MS (OCB positive; p-val-
ue = 2.57610253, OR=2.94, OCB negative; p-val-
ue = 1.5361025, OR=1.88). On the other hand, HLA-
DRB1*04:04 was seen to increase risk of OCB negative MS (p-
value = 0.02, OR=1.58), but confer protection to OCB positive
MS (p-value = 0.04, OR 0.71). HLA-DRB1*01:01 and HLA-
DRB1*07:01 and HLA-DRB1*13:01 alleles were seen to reduce
the risk of both OCB negative and OCB positive MS (OCB
positive; p*01:01 = 7610
210, OR 0.45, p*07:01 = 6610
25, OR 0.57,
p*13:01 = 0.01, OR 0.69, OCB negative; p*01:01 = 2610
25, OR
0.41, p*07:01 = 0.05, OR 0.65, p*13:01 = 0.04, OR 0.59).
DRB1*04:01 was associated with protection for OCB positive
MS only (p-value = 0.0005, OR=0.65) (Figure 1).
Since the HLA-DRB1*15:01 allele appeared as a strong risk
allele skewing the overall allelic distribution at HLA-DRB1, we
next analyzed the association of the other DRB1 alleles after
stratification for DRB1*15:01 to test if these associations
represented real risk effects. The association between OCB
negative MS and HLA-DRB1*04:04 remained significant (p-
value = 0.01), but became non-significant in the OCB positive
group (p-value = 0.74) (Table 4). Associations to HLA-
DRB1*01:01 and *07:01 were reduced, but still nominally
significant, whereas the associations detected at the *13:01 and
*04:01 alleles were non-significant.
Association of HLA-DRB1*03:01 (p-value = 0.0006, OR 1.5) to
OCB positive MS was revealed. When looking at the genotype
distribution, the DRB1*03:01 association could be explained by
excess homozygosity of HLA-DRB1*03:01 in OCB positive
patients (frequency = 3.3%) compared to controls (frequen-
cy = 1.4%), leading to a higher frequency of the HLA-
DRB1*03:01 allele in the patients. The OCB negative group also
showed higher frequency of HLA-DRB1*03:01 homozygotes
(frequency = 4%) compared to controls.
Discussion
This study reports the results of a genome-wide screening and
subsequent replication of a genotype-OCB phenotype analysis in a
total of 4931 genetically homogenous Scandinavian MS patients.
In all stages of the study, we found strong evidence that genetic
differences relating to OCB status of Scandinavian MS patients
could be exerted by HLA class II loci. All HLA associated SNPs in
the screening phase were located in or near HLA class II genes.
Further, high correlation coefficients were estimated between the
top hit HLA SNPs in the screening and the HLA-DRB1*15 and
*04 alleles. Accordingly, we found no evidence of association in
Norwegian samples included in the screening to any of the
identified HLA-SNPs when association to HLA-DRB1*15 or *04
alleles were accounted for in conditional logistic regression
analyses. Of note, the SNP used to tag HLA-DRB1*15:01 in the
MS GWAS (rs3129934) [3] yielded a p-value of 5.1361025 in the
screening phase (data not shown), supporting association of HLA-
DRB1*15:01 to OCB status. Analyses of HLA-DRB1 alleles indeed
showed that OCB positive and OCB negative MS differ by their
association to HLA-DRB1*15. Moreover, HLA-DRB1*15:01 was
a common risk factor for both OCB negative and OCB positive
MS, but exerted a stronger effect on OCB positive MS. On the
other hand, the HLA-DRB1*04:04 allele showed opposite effects
in the two patients groups, i.e. increasing risk of OCB negative MS
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and somewhat protecting against OCB positive MS. These results
confirm the findings from a previous, smaller Swedish study [12].
In addition, we showed that HLA-DRB1*01:01 and *07:01
reduce risk of OCB negative and OCB positive MS. Protective
effects of HLA-DRB1*07 and *01:01 to MS have previously been
reported [25,28,29]. HLA-DRB1*03:01 showed association to
OCB positive MS after stratification for HLA-DRB1*15:01 and
higher frequencies of homozygotes for the HLA-DRB1* 03:01
allele were seen in both OCB negative and OCB positive MS
compared to controls. This complies with an earlier reported
recessive risk for MS conferred by the HLA-DRB1*03 allele [30].
Our data also strongly suggested that rs17411949 in intron 1 of
the CLSTN2 gene at chromosome 3 increased the risk of OCB
negative MS. Variants of this gene have been reported to be
associated with memory and late onset Alzheimer’s disease in
GWASs, but with inconsistent replication [31–33]. CLSTN2 is
predominantly expressed in the brain and is localized in the
postsynaptic membrane of excitatory synapses where it binds
synaptic Ca2+ [34]. However, CLSTN2 is also expressed in bone
marrow, tonsils and Daudi cells (B cell lymphoma) (http://
genome.ucs.edu/), and might have an immunological function.
Further analyses are required to conclude on the indicated
association of this SNP in OCB negative MS.
The relatively low number of OCB negative patients in the
screening phase represents a natural limitation in this study, since
only approximately 10% of MS patients are negative for OCB.
Nevertheless, this study sample is probably the largest available to
date investigating OCB phenotype. Power calculations showed
that with our sample size in the screening phase, the effect size
would need to be OR .2 in order to have 80% power to detect
differences between OCB positive and OCB negative MS at a
significance level of p,1025 (http://ihg2.helmholtz-muenchen.
de/cgi-bin/hw/power2.pl). Hence the p,1025 cut off in the
screening phase could mean that we missed true association of
ORs ,2. A recent study of a German and Belgian MS patient
population reported genome-wide significant association between
quantitative IgG index and a genetic region different from the
findings described in our study, i.e. the IGHC locus [35]. However,
the results of these two studies are not conflicting but
complementary, due to the analysis of differently defined CSF
parameters. Hence, the observed CSF phenotype-genotype
associations in our and the German-Belgian study probably have
different biological implications.
A possible confounding factor in our study is that different
methods were used for OCB detection since sample collection has
been ongoing through many years. The most sensitive method for
OCB detection is IEF [8]. Samples which were collected prior to
the introduction of this method, were investigated by less sensitive
methods, i.e. AGE or IgG index. Since AGE, which was used to
annotate OCB negative MS, is less sensitive than IEF, some of the
earlier collected samples may have been falsely regarded as OCB
negative. However, this would in worst case deflate the association
seen to the OCB negative group, rather than create falsely positive
association, and hence it should not invalidate our positive
findings.
Clinical studies support differences in the outcome in OCB
positive and OCB negative patient groups, albeit with contrasting
findings. In our combined clinical analysis of this Scandinavian
dataset, we find a significantly older AAO in the OCB negative
patients (p-value = 0.01), a trend previously indicated in other
studies [12,16]. A recent study validated this finding and showed a
small, but very significant effect (OR 0.98, p,0.0001) of OCB
status on AAO [10]. The older AAO in the OCB negative group
also speaks against false inclusion of OCB negative patients caused
by lumbar punctures performed in early stages of disease, when
the rate of OCB detection is reported to be lower [36]. We also
found a significantly lower MSSS among the OCB negative
patients included in the replication analysis and the combined
analysis (p-value = 0.02). This is in accordance with most studies of
clinical differences related to OCB status, which suggest a better
outcome for MS patients without OCB, as measured by lower
degree of disability, lower frequencies of exacerbations and slower
progression [10,11,13,15]. On the other hand, a recent Canadian
study in 1120 MS patients did not find any relation between OCB
status and disease progression [37]. The conflicting findings
concerning OCB status and clinical outcome, require further
studies. Finally, therapeutic studies have reported that OCB
negative patients are less likely to develop neutralizing antibodies
Table 3. Conditional logistic regression and correlation analyses of the associated HLA SNPs in the screening in relation to the
HLA-DRB1*15 and *04 alleles.
Norwegian MS samples in
screening (n = 859) Norwegian MS samples in screening genotyped for HLA- DRB1 (n = 822)
HLA SNP_allele p-value pcond *15 Correlation *15 pcond*04 Correlation *04
rs2395157_G 0.008 0.07 20.32 0.87 0.72
rs3817963_G 0.009 0.08 20.32 0.92 0.72
rs3129871_C 0.03 0.96 20.70 0.58 0.41
rs9268906_G 0.001 0.02 20.36 0.49 0.80
rs34083746_G 0.001 0.02 20.32 0.28 0.99
rs3828840_A 0.004 0.43 0.78 0.15 20.38
rs9271640_A 0.001 0.12 0.88 0.05 20.37
rs3129720_A 0.009 0.58 0.71 0.32 20.41
rs9275563_A 0.01 0.08 20.40 0.42 0.65
rs3957148_G 0.0007 0.01 20.27 0.72 0.87
Abbreviations: HLA=Human Leukocyte antigen, pcond =p value of the annotated HLA SNP in logistic regression analyses conditioning on the HLA-DRB1*15 (pcond *15)
or *04 (pcond *04) alleles, correlation*15= correlation coefficient r between annotated HLA SNP and the HLA-DRB1*15 allele, correlation*04 = correlation coefficient r
between annotated HLA SNP and the HLA-DRB1*04 allele.
doi:10.1371/journal.pone.0058352.t003
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to interferon-beta treatment and show better clinical response to
this treatment than their OCB positive counterparts [38,39].
OCB status and the frequency of the HLA-DRB1*15:01 allele
have been shown to vary with latitude [10,40]. In countries like
Sardinia, Japan and Turkey where about five times higher ratios of
OCB negative/OCB positive MS are reported compared to
Northern Europe, MS risk has been shown to be conferred by
both HLA-DRB1*04 and HLA-DRB1*15:01 [10,12,19,41,42].
Hence, we speculate that the HLA-DRB1*15:01 allele possibly
interacts with environmental agents in areas where this allele is
common, making a population more prone to OCB positive MS.
The HLA-DRB1*04 allele may, on the other hand, confer risk of
OCB negative MS by different immuno-genetic mechanisms.
In conclusion, this study points to both distinct and shared
genetic risk factors in Scandinavian MS patients differing by the
presence or absence of OCB in CSF and reveals clinical
differences between the groups. Risk conferred by HLA-
DRB1*15:01 was present in both OCB positive and negative
groups, but was much stronger in the OCB positive group. HLA-
DRB1*04:04 conferred risk for OCB negative MS and protection
of OCB positive MS. HLA-DRB1*01:01 and *07:01 conferred
protection irrespective of OCB status. Moreover, a SNP in the
CLSTN2 gene was associated with increased risk of OCB negative
MS, but requires validation in further studies. The OCB negative
patients had a significantly lower MSSS, were more likely to be
male and had a later age of MS onset. The identified genetic and
clinical differences relating to OCB status in MS may reflect
variation in disease mechanisms and possibly be of importance for
patient management.
Supporting Information
Table S1 SNPs showing association in the screening phase to
OCB status of MS (p,1025).
(DOCX)
Table S2 Analyses of the top hit SNPs in the screening phase
comparing OCB positive and OCB negative MS patients to
healthy controls.
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Figure 1. HLA-DRB1 alleles with significant effects on OCB
positive and negative MS. Figure 1 shows the ORs and 95% CI for
HLA-DRB1 alleles with significant effects on OCB positive and negative
MS. Only alleles which remain significant after stratification for HLA-
DRB1*15:01 allele in both groups are included, except HLA-DRB1*04:04
(not withstanding stratification in the OCB positive group) and HLA-
DRB1* 07:01 (associated to OCB negative MS only after stratification).
These exceptions are marked (*).
doi:10.1371/journal.pone.0058352.g001
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Table S3 The correlation coefficient r between the associated
SNPs in the HLA region and common HLA-DRB1 alleles.
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